摘要
综述罗格列酮的临床研究进展及不良反应。通过对 2型糖尿病病人的空腹血糖和糖基化血红蛋白 Hb A1 c均值变化的比较 ,发现该药与其他抗糖尿病药联合用药优于单独用药 ,对只接受过饮食疗法的病人的效果优于接受过其他抗糖尿病药治疗的病人 ;另外 ,该药的不良反应轻微 ,对肝功能无明显影响。
The progress of clinical study and adverse events of thiazolidine rosiglitazone were reviewed in this article. The clinical effect iveness of rosiglitazone in combination with other antidiabetic agents was better than that of rosiglitazone as monotherapy. Furthermore, the patients with type-2 diabetes mellitus administered with rosiglitazone, who had been previously treated with dietotherapy only, had better effect iveness than those who had been previously treated with one or more other antidiabetic agents. In addition, rosiglitazone has light adverse events and does not cause significant hepatic dysfunction.
出处
《药学服务与研究》
CAS
CSCD
2003年第1期34-37,共4页
Pharmaceutical Care and Research
